Shares of Arcturus Therapeutics dropped by a staggering 11.84% to $52.53 at 11:27 EST on Tuesday, after two consecutive sessions in a row of gains. NASDAQ Composite is dropping 1.72% to $13,300.74, following last session’s downward trend, This seems, up until now, an all-around rough trend trading session today.

Arcturus Therapeutics’s last close was $80.42, 146.93% under its 52-week high of $129.71.

Arcturus Therapeutics’s Sales

Arcturus Therapeutics’s sales growth is a negative 20.5% for the current quarter and 223.5% for the next. The company’s growth estimates for the present quarter and the next is a negative 15.8% and a negative 4.5%, respectively.

Arcturus Therapeutics’s Revenue

Year-on-year quarterly revenue growth declined by 29.7%, now sitting on 10.27M for the twelve trailing months.


Arcturus Therapeutics’s last day, last week, and last month’s average volatility was 10.99%, 6.91%, and 7.17%, respectively.

Arcturus Therapeutics’s last day, last week, and last month’s high and low average amplitude percentage was 11.98%, 12.07%, and 13.11%, respectively.

Arcturus Therapeutics’s Stock Yearly Top and Bottom Value

Arcturus Therapeutics’s stock is valued at $52.53 at 11:27 EST, way below its 52-week high of $129.71 and way above its 52-week low of $8.51.

Arcturus Therapeutics’s Moving Average

Arcturus Therapeutics’s value is way under its 50-day moving average of $68.26 and way below its 200-day moving average of $62.04.


Please enter your comment!
Please enter your name here